Analysis of Adverse Reactions in Cancer Chemotherapy-Constipation Occurring with Co-administration of Anticancer Agents and 5-HT3 Antagonists-

美智男, 木村; 英績, 宇佐美; 忠司, 安田; 桂太郎, 亀井; 正敏, 磯谷

doi:10.5649/jjphcs.33.863

Cited by 3 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The use of 5-hydroxytryptamine (serotonin; 5HT 3 ) receptor antagonist, which is commonly included as part of the pharmacologic treatment of cancer to alleviate emetogenesis, often increases the severity of constipation [ 3 – 5 ]. Although constipation is a significant health issue related to chemotherapy, the incidences of constipation (defined by the Common Terminology Criteria for Adverse Events version 4.0 or CTCAEv4.0 for short) in clinical trials are frequently under-reported as physicians are often not made aware of this symptom [ 4 ]. The incidence of 5HT 3 receptor antagonist-induced constipation increases in conjunction with the emetogenic risk of the chemotherapy medication used.…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of 5HT 3 receptor antagonist-induced constipation increases in conjunction with the emetogenic risk of the chemotherapy medication used. For instance, the incidence rate of constipation with the use of 5-fluorouracil-epidoxorubicin-cyclophosphamide, a regimen with a high emetic risk, is reported to be as high as 84 %, compared to a constipation incidence of 50 % with use of low emetic risk drugs, such as docetaxel and paclitaxel [ 4 , 5 ]. The combination of a 5HT 3 receptor antagonist and a corticosteroid is recommended as an antiemetic prophylaxis in patients with a high or moderate-to-high emetic risk, whereas 5HT 3 is not routinely prescribed to patients with a low emetic risk [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial

Hanai

Ishiguro

Sozu

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

Research on patient-reported outcomes indicates that constipation is a common adverse effect of chemotherapy, and the use of 5-hydroxytryptamine (serotonin; 5HT3) receptor antagonists aggravates this condition. As cancer patients take multiple drugs as a part of their clinical management, a non-pharmacological self-management (SM) of constipation would be recommended. We aimed to evaluate the effectiveness of a SM program on antiemetic-induced constipation in cancer patients. Thirty patients with breast cancer, receiving 5HT3 receptor antagonists to prevent emesis during chemotherapy were randomly assigned to the intervention or control group. The SM program consisted of abdominal massage, abdominal muscle stretching, and education on proper defecation position. The intervention group started the program before the first chemotherapy cycle, whereas patients in the wait-list control group received the program on the day before their second chemotherapy cycle. The primary outcome was constipation severity, assessed by the constipation assessment scale (CAS, sum of eight components). The secondary outcome included each CAS component (0–2 points) and mood states. A self-reported assessment of satisfaction with the program was performed. The program produced a statistically and clinically significant alleviation of constipation severity (mean difference in CAS, −3.00; P = 0.02), decrease in the likelihood of a small volume of stool (P = 0.03), and decrease in depression and dejection (P = 0.02). With regards to program satisfaction, 43.6 and 26.4 % patients rated the program as excellent and good, respectively. Our SM program is effective for mitigating the symptoms of antiemetic-induced constipation during chemotherapy.Electronic supplementary materialThe online version of this article (doi:10.1007/s10549-015-3652-4) contains supplementary material, which is available to authorized users.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial

Hanai

Ishiguro

Sozu

et al. 2015

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Investigation into the Establishment of Indicators for Pharmaceutical Intervention in Cancer Pharmacotherapy

Kimura

2016

YAKUGAKU ZASSHI

View full text Add to dashboard Cite

The present study was conducted to establish pharmaceutical intervention guidelines to enable hospital pharmacists to provide optimal pharmacotherapy to cancer patients. Many patients who use oral anticancer agents showed favorable drug compliance but insu‹cient drug adherence. It was demonstrated that in order to improve drug adherence, it is important to conduct interventions tailored to the patients' conditions so as to encourage interest in their medications, as well as to gain their understanding on the necessity and the side eŠects of their medications. In adjuvant chemotherapy with tegafur/gimeracil/oteracil potassium (S-1) following surgery for stomach cancer, a serum albumin value ＜3.5 g/ dL and a creatinine clearance value ＜80 mL/min were found to signiˆcantly aŠect S-1 dose reduction or termination of the S-1 intake due to side eŠects. Furthermore, patients for whom treatment was discontinued or dosage was reduced demonstrated a large reduction in body mass index. When adding insulin to an at-home high-calorie infusion, the insulin retention rate decreased when the number of grams of sugar level per 1 g of sodium bisulˆte in the infusion (G/g) was  364.6, whereas the insulin retention rate did not decrease when G/g was  466.0. Ourˆndings in the present study can serve as highly useful guidelines when pharmacists working in clinical settings conduct pharmaceutical interventions in pharmacotherapy for cancer.

show abstract

Survey on Adverse Events with Use of Antiemetics during Anti-cancer Chemotherapy

Yasukawa¹,

Kaise²,

Tanaka³

et al. 2011

Jpn. J. Pharm. Health Care Sci.

View full text Add to dashboard Cite

Analysis of Adverse Reactions in Cancer Chemotherapy-Constipation Occurring with Co-administration of Anticancer Agents and 5-HT3 Antagonists-

Cited by 3 publications

References 6 publications

Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial

Effects of a self-management program on antiemetic-induced constipation during chemotherapy among breast cancer patients: a randomized controlled clinical trial

Investigation into the Establishment of Indicators for Pharmaceutical Intervention in Cancer Pharmacotherapy

Survey on Adverse Events with Use of Antiemetics during Anti-cancer Chemotherapy

Contact Info

Product

Resources

About